26789 Analysis of cutaneous T cell lymphoma hospitalizations in the United States

2021 ◽  
Vol 85 (3) ◽  
pp. AB25
Author(s):  
Ehizogie Edigin ◽  
Precious Obehi Eseaton
1983 ◽  
Vol 309 (5) ◽  
pp. 257-264 ◽  
Author(s):  
Paul A. Bunn ◽  
Geraldine P. Schechter ◽  
Elaine Jaffe ◽  
Douglas Blayney ◽  
Robert C. Young ◽  
...  

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e19505-e19505
Author(s):  
A. M. Babbo ◽  
M. Chokshi ◽  
A. Rademaker ◽  
B. Mittal

e19505 Background: Primary cutaneous lymphomas occur in 0.5 to 1 per 100,000 people every year in developed countries. Less than 1,000 cases of Mycosis Fungoides are diagnosed each year in the United States, with approximately 3 cases per 1,000,000 per year. Cutaneous T-cell lymphomas are responsive to radiation therapy, and local radiation therapy, total skin electron beam therapy, phototherapy (with UVB or PUVA), chemotherapy agents (nitrogen mustards, BCNU), retinoids, and steroids have all been used with varying degrees of success. Methods: This is a retrospective review of all cases of histology-proven cutaneous T-cell lymphoma treated with single-fraction radiation therapy at Northwestern Memorial Hospital in the Department of Radiation Oncology since 1990. We looked at response to treatment and local control. We reviewed the charts of 67 patients with cutaneous T-cell lymphoma, of which 40 patients and a total of 130 sites of disease received single-fraction radiation therapy and had available follow-up data. Results: Of the 130 lesions receiving a single-fraction of radiation, 86 (66%) received 800cGy in 1 fraction and 38 (29%) received 700cGy. 4 patients (3%) received 750cGy, 1 (<1%) received 550cGy and 1 (<1%) received 500cGy. Patients were treated with electron energies ranging from 6–18 MeV or photon energies ranging from 4–10 MV. Out of 130 lesions, 119 (92%) achieved a complete response (CR) to single-fraction radiation and 11 (8%) achieved a partial response (PR). There were 2 sites of relapse out of 130 treated sites, involving 2 patients. The median follow-up time was 4 months, mean follow-up time was 14 months, and 44% of patients had greater than 6 months of follow-up. Conclusions: This review of the experience at our institution since 1990 shows single-fraction radiation therapy to be an effective treatment for cutaneous T-cell lymphoma, with high response rates and very low relapse rates. No significant financial relationships to disclose.


Cancer ◽  
2011 ◽  
Vol 118 (15) ◽  
pp. 3786-3792 ◽  
Author(s):  
Reem Z. Sharaiha ◽  
Ben Lebwohl ◽  
Laura Reimers ◽  
Govind Bhagat ◽  
Peter H. Green ◽  
...  

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2370-2370
Author(s):  
Lauren Pinter-Brown ◽  
Tami Wisniewski ◽  
Bozena Katic ◽  
Sheenu Chandwani ◽  
Ya-Ting Chen

Abstract Background: Several systemic therapies are available for patients with cutaneous T-cell lymphoma (CTCL). However, little is known about physicians’ familiarity with and utilization of these therapies. To address this issue, we conducted a web-based survey among physicians treating CTCL with systemic therapies in the United States. Methods: We surveyed a geographically representative panel of dermatologists and oncologists in September 2007. Physicians had to have treated at least one CTCL patient systemically over the past two years and been practicing medicine for &gt;2 years. Individual systemic therapies were grouped according to NCCN guidelines as Category A (ECP, bexarotene, denileukin diftitox, interferon, vorinostat, and methotrexate) or Category B therapies (gemcitabine, CHOP, and doxorubicin). Chi-square or Fisher’s exact tests assessed statistical differences between specialties. Results: A total of 250 physicians participated; 128 dermatologists and 122 oncologists. Mean age was 47.5 (std =9.9) years and 20.0% were female. Significantly more (p &lt; 0.0001) dermatologists than oncologists reported being not or somewhat familiar with denileukin diftitox (49.2% vs. 14.8%), gemcitabine (71.1% vs.7.4%), doxorubicin (57.8% vs. 5.7%), CHOP (33.6% vs. 1.6%) and vorinostat (67.2% vs. 36.9%). Overall, use of Category A therapies decreased in later stage disease while use of Category B therapies increased. Dermatologists chose Category A therapies and referred patients more frequently, whereas oncologists chose Category B therapies and referred less frequently. Conclusions: Familiarity with and utilization of systemic therapies for CTCL differ by physician specialty. Educational efforts aimed at highlighting advances in CTCL treatment and newly implemented treatment guidelines may help optimize patient care.


Sign in / Sign up

Export Citation Format

Share Document